CD69 expression in lung and breast cancer tumors were positively correlated with immune checkpoint expression, T cell infiltration, and ImmunoPhenoScore (IPS) (85), leading the authors to propose CD69 as predictive biomarkers for ICI treatment response (8). The gene discussed is CD69; the disease is breast carcinoma.